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Understanding the genetic basis of complex brain disorders is critical for developing rational therapeutics. In the past decade, genome-wide association studies (GWASs) have 
identified thousands of highly significant loci1–4. However, interpre-
tation of GWASs remains challenging. First, >90% of the identified 
variants are located in noncoding regions5, complicating precise 
identification of risk genes. Second, extensive linkage disequilib-
rium present in the human genome confounds efforts to pinpoint 
causal variants. Finally, it remains unclear in which tissues and cell 
types these variants are active, and how they disrupt specific bio-
logical networks to impact disease risk.
Functional genomic studies of the brain are now seen as critical 
for interpretation of GWAS findings, as they can identify functional 
regions (for example, open chromatin, enhancers and transcription-
factor-binding sites) and target genes (via chromatin interactions 
and expression quantitative trait loci)6. Gene regulation varies sub-
stantially across tissues and cell types7,8, and hence it is critical to 
perform functional genomic studies in empirically identified cell 
types or tissues.
Multiple groups have developed strategies to identify tissues 
associated with complex traits9–13, but few have focused on the iden-
tification of salient cell types within a tissue. Furthermore, previ-
ous studies used a small number of cell types derived from one or 
few different brain regions3,11–17. For example, we recently showed 
that, among 24 brain cell types, 4 types of neuron were consistently 
associated with schizophrenia11. We were explicit that this conclu-
sion was limited by the relatively few brain regions studied; other 
cell types from unsampled regions could conceivably contribute to 
the disorder.
Here, we integrate a wider range of gene expression data—tissues 
across the human body and single-cell gene expression data from an 
entire nervous system—to identify tissues and cell types underlying 
a large number of complex traits (Fig. 1a,b). We find that psychi-
atric and cognitive traits are generally associated with similar cell 
types whereas neurological disorders are associated with different 
cell types. Notably, we show that Parkinson’s disease is associated 
with cholinergic and monoaminergic neurons, enteric neurons and 
oligodendrocytes, providing new clues into its etiology.
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Genome-wide association studies have discovered hundreds of loci associated with complex brain disorders, but it remains 
unclear in which cell types these loci are active. Here we integrate genome-wide association study results with single-cell tran-
scriptomic data from the entire mouse nervous system to systematically identify cell types underlying brain complex traits. We 
show that psychiatric disorders are predominantly associated with projecting excitatory and inhibitory neurons. Neurological 
diseases were associated with different cell types, which is consistent with other lines of evidence. Notably, Parkinson’s dis-
ease was genetically associated not only with cholinergic and monoaminergic neurons (which include dopaminergic neurons) 
but also with enteric neurons and oligodendrocytes. Using post-mortem brain transcriptomic data, we confirmed alterations in 
these cells, even at the earliest stages of disease progression. Our study provides an important framework for understanding 
the cellular basis of complex brain maladies, and reveals an unexpected role of oligodendrocytes in Parkinson’s disease.
glycemic controls in individuals with diabetes, was associated with 
the pancreas, liver and stomach (Fig. 1d). Stroke and coronary 
artery disease were most associated with blood vessels and waist-
to-hip ratio was most associated with adipose tissue (Fig. 1d and 
Supplementary Fig. 1).
For brain-related traits (Fig. 1c, Supplementary Fig. 1 and 
Supplementary Table 1), 13 of 18 traits were significantly associ-
ated with 1 or more GTEx brain regions. For example, schizophre-
nia, intelligence, educational attainment, neuroticism, body mass 
index (BMI) and major depressive disorder (MDD) were most sig-
nificantly associated with the brain cortex, frontal cortex or anterior 
cingulate cortex, while Parkinson’s disease was most significantly 
associated with the substantia nigra (as expected) and spinal cord 
(Fig. 1c). Alzheimer’s disease was associated with tissues with prom-
inent roles in immunity (blood and spleen) consistent with other 
studies16,20,21, but also with the substantia nigra and spinal cord, 
while stroke was associated with blood vessels (consistent with a 
role of arterial pathology in stroke)22.
In conclusion, we show that tissue-level gene expression allows 
identification of relevant tissues for complex traits, indicating that 
our methodology is suitable to explore associations between trait 
and gene expression at the cell-type level.
Association of brain complex traits with cell types. We leveraged 
gene expression data from 39 broad categories of cell types from the 
mouse central and peripheral nervous system23 to systematically map 
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Fig. 1 | Study design and tissue-level associations. a, Heat map of associations between trait and tissue/cell type (−log10[P]) for the selected traits.  
b, Associations between trait and tissue/cell type were performed using MAGMA and LDSC (testing for enrichment in genetic association of the 10% 
most specific genes in each tissue/cell type). c, Tissue–trait associations for selected brain-related traits. d, Tissue–trait associations for selected  
non-brain-related traits. The mean strength of association (−log10[P]) of MAGMA and LDSC is shown, and the bar color indicates whether the tissue is 
significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate). IBD, inflammatory bowel disease.
Results
Association of traits with tissues by using bulk RNA sequencing. 
Our goal was to use GWAS results to identify relevant tissues and 
cell types. Our primary focus was human phenotypes whose etio-
pathology is based in the central nervous system (CNS). We thus 
obtained 18 sets of GWAS summary statistics for brain-related com-
plex traits. For comparison, we included GWAS summary statistics 
for eight diseases and traits with large sample sizes whose etiopa-
thology is not rooted in the CNS (Methods).
We first aimed to identify human tissues showing enrichment for 
genetic associations using bulk-tissue RNA sequencing (RNA-seq; 
37 tissues) from the Genotype-Tissue Expression (GTEx) project7.  
To robustly identify tissues implied by these 26 GWASs, we used 
2 approaches (MAGMA18 and LDSC12,19) that employ different 
assumptions (Methods). For both methods, we tested whether the 
10% most specific genes in each tissue were enriched in genetic 
associations with the different traits (Fig. 1b).
Examination of non-brain-related traits found, as 
expected, associations with salient tissues. For example, as 
shown in Fig. 1d  and Supplementary Table 1, inflammatory 
bowel disease was strongly associated with immune tissues 
(blood and spleen) and alimentary tissues impacted by the 
disease (small intestine and colon). Lung and adipose tissues 
were also significantly associated with inflammatory bowel 
disease, possibly because of the high spec-ificity of immune genes 
in these two tissues (Extended Data Fig. 1). Type 2 diabetes was 
associated with the pancreas, while hemoglo-bin A1C, which is 
used to diagnose type 2 diabetes and monitor  
Our use of mouse data to inform human genetic findings was care-
fully considered (see Discussion).
As in our previous study of schizophrenia based on a small num-
ber of brain regions11, we found the strongest signals for telencepha-
lon projecting neurons (that is, excitatory neurons from the cortex, 
hippocampus and amygdala), telencephalon projecting inhibitory 
neurons (that is, medium spiny neurons from the striatum) and 
telencephalon inhibitory neurons (Fig. 2a and Supplementary 
Table 2). We also found that other types of neuron were associated 
with schizophrenia albeit less significantly (for example, dentate 
gyrus granule neurons). Other psychiatric and cognitive traits had 
similar cellular association patterns to schizophrenia (Extended 
Data Figs. 2 and 3 and Supplementary Table 2). We did not observe 
significant associations with immune or vascular cells for any 
psychiatric disorders or cognitive traits.
Neurological disorders generally implicated fewer cell types, 
possibly because the neurological GWAS had a lower signal than 
the GWASs of cognitive, anthropometric and psychiatric traits 
(Supplementary Fig. 2). Consistent with the genetic correlations 
(Supplementary Note), the pattern of associations for neurological 
disorders was distinct from that of psychiatric disorders (Extended 
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Fig. 2 | Association of selected brain-related traits with cell types from the entire nervous system. a, Associations of the 10 most associated cell types.  
b, Conditional analysis results for Parkinson’s disease using MAGMA. The label indicates the cell type the association analysis is being conditioned on.  
The mean strength of association (−log10[P]) of MAGMA and LDSC is shown, and the bar color indicates whether the cell type is significantly associated 
with both methods, one method or none (significance threshold: 5% false discovery rate).
Data Figs. 2 and 3), reflecting that neurological disorders have mini-
mal functional overlap with psychiatric disorders24.
Stroke was significantly associated with vascular smooth muscle 
cells (Fig. 2a), consistent with an important role of vascular pro-
cesses for this trait. Alzheimer’s disease had the strongest signal in 
microglia, as reported previously10,16,25, but the association did not 
survive multiple testing correction.
We found that Parkinson’s disease was significantly 
associated with cholinergic and monoaminergic neurons (Fig. 
2a). This clus-ter consists of neurons (Supplementary Table 3) 
that are known to degenerate in Parkinson’s disease26–28, such as 
dopaminergic neu-rons from the substantia nigra (the hallmark of 
Parkinson’s disease), but also serotonergic and glutamatergic 
neurons from the raphe nucleus29, noradrenergic neurons30, 
and neurons from afferent nuclei in the pons31 and the 
medulla (the brain region associated with the earliest lesions in 
Parkinson’s disease26). In addition, hind-brain neurons and 
peptidergic neurons were also significantly asso-ciated with 
Parkinson’s disease (with LDSC alone). Interestingly, we also 
found that enteric neurons were significantly associated with 
Parkinson’s disease (Fig. 2a), which is consistent with Braak’s 
hypothesis, which postulates that Parkinson’s disease could start 
in 
that the patterns of associations were largely unaffected. Similarly, 
we found that controlling for educational attainment had little effect 
on the schizophrenia associations and vice versa (Extended Data 
Fig. 5). In other words, genes driving the cell-type associations of 
schizophrenia appear to be distinct from genes driving the cell-type 
associations of cognitive traits.
Trait and cell-type associations conditioning on cell types. Many 
neuronal cell types passed our stringent significance threshold for 
multiple brain traits (Fig. 2a). This could be because gene expres-
sion profiles are highly correlated across cell types and/or because 
many cell types are independently associated with the different 
traits. To address this, we performed univariate conditional analy-
sis using MAGMA, testing whether cell-type associations remained 
significant after controlling for the 10% most specific genes from 
other cell types (Supplementary Table 5). We observed that multi-
ple cell types were independently associated with age at menarche, 
anorexia, autism, bipolar disorder, BMI, educational attainment, 
intelligence, MDD, neuroticism and schizophrenia (Supplementary 
Fig. 4). As in our previous study11, we found that the association 
between schizophrenia and telencephalon projecting inhibitory 
neurons (that is, medium spiny neurons) was independent from 
telencephalon projecting excitatory neurons (that is, pyramidal 
neurons). For Parkinson’s disease, enteric neurons, oligodendro-
cytes and cholinergic and monoaminergic neurons were indepen-
dently associated with the disorder (Fig. 2b), suggesting that these 
three different cell types play an independent role in the etiology 
of the disorder.
Replication in other single-cell RNA-seq datasets. To assess the 
robustness of our results, we repeated these analyses in independent 
datasets. A key caveat is that these other datasets did not sample the 
entire nervous system as in the analyses above.
First, we used a single-cell RNA-seq dataset that identified 88 
broad categories of cell types from 9 mouse brain regions34. We 
found similar patterns of association in this external dataset (Fig. 3a, 
Extended Data Fig. 6 and Supplementary Table 6). Notably, for 
schizophrenia, we strongly replicated associations with neurons 
from the cortex, hippocampus and striatum. We also observed simi-
lar cell-type associations for other psychiatric and cognitive traits 
(Fig. 3a and Extended Data Figs. 6 and 7). For neurological disor-
ders, we found that stroke was significantly associated with mural 
cells while Alzheimer’s disease was significantly associated with 
microglia (Extended Data Fig. 6). The associations of Parkinson’s 
disease with neurons from the substantia nigra and oligodendro-
cytes were significant at a nominal level in this dataset (P = 0.006 for 
neurons from the substantia nigra; P = 0.027 for oligodendrocytes 
using LDSC). By computing gene expression specificity within neu-
rons, we replicated our findings that neurons from the cortex can 
be prioritized for multiple traits (schizophrenia, bipolar disorder, 
educational attainment, intelligence, BMI, neuroticism, MDD and 
anorexia; Extended Data Fig. 8).
Second, we reanalyzed these GWAS datasets using our previous 
dataset11 (24 cell types from 5 mouse brain regions; Fig. 3b, Extended 
Data Fig. 9 and Supplementary Table 7). We again found strong 
associations of pyramidal neurons from the somatosensory cortex, 
pyramidal neurons from region 1 of the cornu ammonis (CA1) of 
the hippocampus (both corresponding to telencephalon projecting 
excitatory neurons in our main dataset) and medium spiny neu-
rons from the striatum (corresponding to telencephalon projecting 
inhibitory neurons) with psychiatric and cognitive traits. MDD and 
autism were most associated with neuroblasts, while intracranial 
volume was most associated with neural progenitors. The associa-
tion of dopaminergic adult neurons with Parkinson’s disease was 
significant at a nominal level using LDSC (P = 0.01), while oligo-
dendrocytes did not replicate in this dataset, perhaps because they 
the gut and travel to the brain via the vagus nerve32,33. Furthermore, 
we found that oligodendrocytes (mainly sampled in the midbrain, 
medulla, pons, spinal cord and thalamus; Supplementary Fig. 3) 
were significantly associated with Parkinson’s disease, indicating a 
strong glial component to the disorder. This finding was unexpected 
but consistent with the strong association of the spinal cord at the 
tissue level (Fig. 1c), as the spinal cord contains the highest propor-
tion of oligodendrocytes (71%) in the nervous system23. Together, 
these findings provide genetic evidence for a role of enteric neurons, 
cholinergic and monoaminergic neurons, and oligodendrocytes in 
Parkinson’s disease etiology.
Neuronal prioritization in the mouse CNS. A key goal of this 
study was to prioritize specific cell types for follow-up experimental 
studies. As our metric of gene expression specificity was computed 
based on all cell types in the nervous system, it is possible that the 
most specific genes in a given cell type capture genes that are shared 
within a high-level category of cell types (for example, neurons). To 
rule out this possibility, we computed new specificity metrics based 
only on neurons from the CNS. We then tested whether the 10% 
most specific genes for each CNS neuron were enriched in genetic 
association for the brain-related traits that had a significant associa-
tion with a CNS neuron (13/18) in our initial analysis.
Using the CNS neuron gene expression specificity metrics, we 
observed a reduction in the number of neuronal cell types associ-
ated with the different traits (Extended Data Fig. 4), suggesting that 
some of the signal was driven by core neuronal genes. However, we 
found that multiple neuronal cell types remained associated with 
a number of traits. For example, we found that telencephalon pro-
jecting excitatory and projecting inhibitory neurons were strongly 
associated with schizophrenia, bipolar disorder, educational attain-
ment and intelligence using both LDSC and MAGMA. Similarly, 
telencephalon projecting excitatory neurons were significantly 
associated with BMI, neuroticism, MDD, autism and anorexia using 
one of the two methods, while hindbrain neurons and cholinergic 
and monoaminergic neurons remained significantly associated with 
Parkinson’s disease.
Together, these results suggest that specific types of CNS  
neuron can be prioritized for follow-up experimental studies for 
multiple traits.
Trait and cell-type associations conditioning on other traits. As 
noted above, the patterns of associations of psychiatric and cogni-
tive traits were highly correlated across the 39 different cell types 
tested (Extended Data Fig. 3). For example, the Spearman rank 
correlation of cell-type associations (−log10[P]) between schizo-
phrenia and intelligence was 0.96 (0.94 for educational attainment) 
as both traits had the strongest signal in telencephalon projecting 
excitatory neurons and little signal in immune or vascular cells. In 
addition, we observed that genes driving the association signal in 
the top cell types of the two traits were enriched in relatively simi-
lar Gene Ontology (GO) terms involving neurogenesis and synaptic 
processes (Supplementary Note). We evaluated two possible expla-
nations for these findings: schizophrenia and intelligence are both 
associated with the same genes that are specifically expressed in the 
same cell types; or schizophrenia and intelligence are associated 
with different sets of genes that are both specific to the same cell 
types. Given that these two traits have a significant negative genetic 
correlation (rg = −0.22, from GWAS results alone) (Supplementary 
Table 4), we hypothesized that the strong overlap in cell-type asso-
ciations for schizophrenia and intelligence was due to the second 
explanation.
To evaluate these hypotheses, we tested whether the 10% 
most specific genes for each cell type were enriched in genetic 
associa-tions for schizophrenia controlling for the gene-level 
genetic asso-ciation of intelligence using MAGMA (and vice 
versa) and found 
were not sampled from the regions affected by the disorder (that is, 
spinal cord, pons, medulla or midbrain). A within-neuron analysis 
again found that projecting excitatory (that is, pyramidal CA1) and 
projecting inhibitory neurons (that is, medium spiny neurons) can 
be prioritized for multiple traits (schizophrenia, bipolar disorder, 
intelligence, educational attainment and BMI). In addition, neuro-
blasts could be prioritized for MDD and neural progenitors could 
be prioritized for intracranial volume (Extended Data Fig. 10).
Third, we evaluated a human dataset consisting of 15 differ-
ent cell types from the cortex and hippocampus35 (Fig. 4a and 
Supplementary Table 8). We replicated our findings with psychiatric 
and cognitive traits being associated with pyramidal neurons (excit-
atory) and interneurons (inhibitory) from the somatosensory cortex 
and hippocampus. We also replicated the association of Parkinson’s 
disease with oligodendrocytes (enteric neurons and cholinergic and 
monoaminergic neurons were not sampled in this dataset). No cell 
types reached our significance threshold using specificity metrics 
computed within neurons, possibly because of similarities in the 
transcriptomes of neurons from the cortex and hippocampus.
Fourth, we evaluated a human dataset consisting of 35 different 
cell types from 3 different brain regions (visual cortex, frontal cortex 
and cerebellum) (Fig. 4b and Supplementary Table 9)36. We found 
that schizophrenia, educational attainment, neuroticism and BMI 
were associated with excitatory neurons, while bipolar disorder was 
associated with both excitatory and inhibitory neurons. As observed 
previously10,16,25, Alzheimer’s disease was significantly associated 
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Fig. 3 | Replication of associations between cell type and trait in mouse datasets. a, Tissue–trait associations for the 10 most associated cell types among 88 
cell types from 9 different brain regions. b, Tissue–trait associations for the 10 most associated cell types among 24 cell types from 5 different brain regions. 
The mean strength of association (−log10[P]) of MAGMA and LDSC is shown, and the bar color indicates whether the cell type is significantly associated 
with both methods, one method or none (significance threshold: 5% false discovery rate). SS, somatosensory cortex; CA1, cornu ammonis region 1.
with microglia. Oligodendrocytes were not significantly associated 
with Parkinson’s disease in this dataset, again possibly because the 
spinal cord, pons, medulla and midbrain were not sampled. No cell 
types reached our significance threshold using specificity metrics 
computed within neurons in this dataset.
Validation of oligodendrocyte pathology in Parkinson’s dis-
ease. We investigated the role of oligodendrocytes in Parkinson’s 
disease. First, we confirmed the association of oligodendro-
cytes with Parkinson’s disease by combining evidence across all 
datasets (Fisher’s combined probability test, P = 2.5 × 10−7 using 
MAGMA and 6.3 × 10−3 using LDSC; Supplementary Table 2 and 
Supplementary Fig. 5). In addition, oligodendrocytes remained 
significantly associated with Parkinson’s disease after conditioning 
on the top neuronal cell type in each dataset (P = 1.2 × 10−7, Fisher’s 
combined probability test).
Second, we tested whether genes with rare variants associated 
with parkinsonism (Supplementary Table 10) were specifically 
expressed in cell types from the mouse nervous system (Methods). 
As for the common variant, we found the strongest enrichment for 
cholinergic and monoaminergic neurons (Supplementary Table 11). 
However, we did not observe any significant enrichments for oligo-
dendrocytes or enteric neurons for these genes.
Third, we applied expression-weighted cell-type 
enrichment (EWCE)10 to test whether genes that are 
upregulated/downregu-lated in post-mortem brains from humans 
with Parkinson’s disease 
substantia nigra, and consistently, we found that downregulated genes 
were not enriched in dopaminergic neurons at this stage. Notably, 
upregulated genes were already strongly enriched in oligodendro-
cytes at Braak stages 1–2. These results not only support the genetic 
evidence indicating that oligodendrocytes may play a causal role in 
Parkinson’s disease but also indicate that their involvement precedes 
the emergence of pathological changes in the substantia nigra.
Discussion
In this study, we used gene expression data from cells sampled from 
the entire nervous system to systematically map cell types to GWAS 
results from multiple psychiatric, cognitive and neurological com-
plex phenotypes.
We note several limitations. First, we emphasize that we can impli-
cate a particular cell type, but it is premature to exclude cell types 
for which we do not have data11. Second, we used gene expression 
data from mice to understand human phenotypes. We believe our 
approach is appropriate for several reasons. First, crucially, the key 
findings were replicated in human data. Second, single-cell RNA-seq 
is achievable in mouse but difficult in human neurons (where single-
nuclei RNA-seq is typical35,36,42,43). In the brain, differences between 
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Fig. 4 | Human replication of associations between cell type and trait. a, Associations between cell type and trait for 15 cell types (derived from single-
nuclei RNA-seq) from 2 different brain regions (cortex and hippocampus). b, Associations between cell type and trait for 35 cell types (derived from single-
nuclei RNA-seq) from 3 different brain regions (frontal cortex, visual cortex and cerebellum). The mean strength of association (−log10[P]) of MAGMA and 
LDSC is shown, and the bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 
5% false discovery rate). INT, intelligence; SCZ, schizophrenia; EDU, educational attainment; NEU, neuroticism; BMI, body mass index; BIP, bipolar disorder; 
MDD, major depressive disorder; MEN, age at menarche; ASD, autism spectrum disorder; MIG, migraine; PAR, Parkinson’s disease; ADHD, attention 
deficit hyperactivity disorder; ICV, intracranial volume; HIP, hippocampal volume; AN, anorexia nervosa; ALZ, Alzheimer’s disease; ALS, amyotrophic lateral 
sclerosis; STR, stroke. SS1, somatosensory cortex type 1; SS2, somatosensory cortex type 2; CA1, cornu ammonis region 1; CA3, cornu ammonis region 3.
(from six separate cohorts) were enriched in cell types located in the 
substantia nigra and ventral midbrain (Fig. 5). Three of the stud-
ies had a case–control design and measured gene expression in: the 
substantia nigra of 9 controls and 16 cases37; the medial substantia 
nigra of 8 controls and 15 cases38; and the lateral substantia nigra of 
7 controls and 9 cases38. In all three studies, downregulated genes in 
Parkinson’s disease were specifically enriched in dopaminergic neu-
rons (consistent with the loss of this particular cell type in disease), 
while upregulated genes were significantly enriched in cells from 
the oligodendrocyte lineage. This suggests that an increased oligo-
dendrocyte activity or proliferation could play a role in Parkinson’s 
disease etiology. Surprisingly, no enrichment was observed for 
microglia, despite recent findings39,40.
We also analyzed gene expression data from post-mortem 
human brains that had been scored by neuropathologists for 
their Braak stage41. Differential expression was calculated 
between brains with Braak scores of 0 (controls) and brains with 
Braak scores of 1–2, 3–4 and 5–6. At the later stages (Braak scores 
3–4 and 5–6), downregu-lated genes were specifically expressed 
in dopaminergic neurons, while upregulated genes were 
specifically expressed in oligoden-drocytes (Fig. 5), as observed in 
the case–control studies. Moreover, Braak stages 1 and 2 are 
characterized by little degeneration in the 
that are missed by sequencing nuclei are important for psychiat-
ric disorders11, and we previously showed that dendritically trans-
ported transcripts are specifically depleted from nuclei datasets11 
(confirmed in four additional datasets; Supplementary Fig. 6). 
Third, correlations in gene expression for cell type across species are 
high (median correlation 0.68; Supplementary Fig. 7), and as high 
as or higher than correlations across methods within cell type and 
species (single-cell versus single-nuclei RNA-seq, median correla-
tion 0.6)44. Fourth, we evaluated only protein-coding genes with 1:1 
orthologs between mice and humans, which are highly conserved. 
Fifth, we previously showed that gene expression data cluster by 
cell type and not by species11, indicating broad conservation of core 
brain cellular functions across species. Sixth, we used a large num-
ber of genes to map cell types to traits (~1,500 genes for each cell 
type), minimizing potential bias due to individual genes differen-
tially expressed across species. Seventh, if there were strong differ-
ences in cell-type gene expression between mice and humans, we 
would not expect that specific genes in mouse cell types would be 
enriched in genetic associations with human disorders. However, it 
remains possible that some cell types have different gene expression 
patterns between mice and humans, are present in only one species, 
have a different function or are involved in different brain circuits.
A third limitation is that gene expression data were from adoles-
cent mice. Although many psychiatric and neurological disorders 
have onsets in adolescence, some have onsets earlier (autism) or 
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Fig. 5 | Enrichment of Parkinson’s disease differentially expressed genes in cell types from the substantia nigra. Enrichment of the 500 most 
upregulated/downregulated genes (Braak stage 0 versus Braak stages 1–2, 3–4 and 5–6, as well as cases versus controls) in post-mortem human 
substantia nigra gene expression samples. The enrichments were obtained using EWCE10. An asterisk shows significant enrichments after multiple testing 
correction (P < 0.05/(25 × 6)). SNc, substantia nigra par compacta; VTA, ventral tegmental area.
later (Alzheimer’s and Parkinson’s disease). It is thus possible that 
some cell types are vulnerable at specific developmental times. 
Data from studies mapping cell types across brain development and 
aging are required to resolve this issue.
We found that psychiatric traits implicated largely similar cell 
types. These biological findings are consistent with genetic and epi-
demiological evidence of a general psychopathy factor underlying 
diverse psychiatric disorders24,45,46. Although intelligence and edu-
cational attainment implicated similar cell types, conditional analy-
ses showed that the same cell types were implicated for different 
reasons. This suggests that different sets of genes highly specific to 
the same cell types contribute independently to schizophrenia and 
cognitive traits.
Our findings for neurological disorders were strikingly different 
from those for psychiatric disorders. We found, in contrast to pre-
vious studies that either did not identify any cell-type associations 
with Parkinson’s disease47 or identified significant associations with 
cell types from the adaptive immune system40, that cholinergic and 
monoaminergic neurons (which include dopaminergic neurons), 
enteric neurons and oligodendrocytes were significantly and inde-
pendently associated with the disease. Our findings suggest that 
dopaminergic neuron loss in Parkinson’s disease (the hallmark of 
the disease) is at least partly due to intrinsic biological 
mechanisms.
Interestingly, enteric neurons were also associated with 
Parkinson’s disease. This result is in line with prior 
evidence  
implicating the gut in Parkinson’s disease. Notably, dopaminergic 
defects and Lewy bodies (that is, abnormal aggregates of proteins 
enriched in α-synuclein) are found in the enteric nervous system 
of individuals affected by Parkinson’s disease48,49. In addition, Lewy 
bodies have been observed in individuals up to 20 years before their 
diagnosis50, and sectioning of the vagus nerve (which connects the 
enteric nervous system to the CNS) was shown to reduce the risk 
of developing Parkinson’s disease51. Therefore, our results linking 
enteric neurons with Parkinson’s disease provide new genetic evi-
dence for Braak’s hypothesis32.
The association of oligodendrocytes with Parkinson’s disease 
was more unexpected. A possible explanation is that this associa-
tion could be due to a related disorder (for example, multiple-sys-
tem atrophy, characterized by parkinsonism and accumulation of 
α-synuclein in glial cytoplasmic inclusions52). However, this expla-
nation is unlikely as multiple-system atrophy is a very rare disor-
der; hence, only a few individuals could have been included in the 
Parkinson’s disease GWAS. In addition, misdiagnosis is unlikely to 
have led to the association of Parkinson’s disease with oligodendro-
cytes. Indeed, we found a high genetic correlation between self-
reported diagnosis from the 23andMe cohort and a previous GWAS 
of clinically ascertained Parkinson’s disease53.
We did not find an association of oligodendrocytes with parkin-
sonism for genes affected by rare variants. This result may reflect 
etiological differences between sporadic and familial forms of the 
disease or low statistical power. Previous evidence has suggested an 
involvement of oligodendrocytes in Parkinson’s disease. For exam-
ple, α-synuclein-containing inclusions have been reported in oligo-
dendrocytes in the brains of individuals with Parkinson’s disease54. 
These inclusions (‘coiled bodies’) are typically found throughout 
the brainstem nuclei and fiber tracts55. Although the presence of 
coiled bodies in oligodendrocytes is a common, specific and well-
documented neuropathological feature of Parkinson’s disease, the 
importance of this cell type and its early involvement in disease has 
not been fully recognized. Our findings suggest that alterations in 
oligodendrocytes occur at an early stage of disease, which precedes 
neurodegeneration in the substantia nigra, arguing for a key role of 
this cell type in Parkinson’s disease etiology.
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Methods
GWAS results. Our goal was to use GWAS results to identify relevant tissues and 
cell types. Our primary focus was human phenotypes whose etiopathology is based 
in the CNS. We thus obtained 18 sets of GWAS summary statistics from European 
samples for brain-related complex traits. These were selected because they had at 
least one genome-wide significant association (as of 2018; for example, Parkinson’s 
disease, schizophrenia and IQ (intelligence quotient)). For comparison, we 
included GWAS summary statistics for eight diseases and traits with large sample 
sizes whose etiopathology is not rooted in the CNS (for example, type 2 diabetes). 
The selection of these conditions allowed contrasts of tissues and cells highlighted 
by our primary interest in brain phenotypes with non-brain-related traits.
The phenotypes were: schizophrenia1, educational attainment2, intelligence14, 
BMI4, bipolar disorder56, neuroticism3, MDD57, age at menarche58, autism59, 
migraine60, amyotrophic lateral sclerosis61, ADHD62, Alzheimer’s disease16, age at 
menopause63, coronary artery disease64, height4, hemoglobin A1c65, hippocampal 
volume66, inflammatory bowel disease67, intracranial volume68, stroke69, type 2 
diabetes mellitus70, type 2 diabetes adjusted for BMI70, waist–hip ratio adjusted for 
BMI71 and anorexia nervosa72.
For Parkinson’s disease, we performed an inverse-variance-weighted meta-
analysis73 using summary statistics from Nalls et al.53 (9,581 cases, 33,245 controls) 
and summary statistics from 23andMe (12,657 cases, 941,588 controls). We 
found a very high genetic correlation (rg)74 between the results from these cohorts 
(rg = 0.87, s.e. = 0.068) with little evidence of sample overlap (LDSC bivariate 
intercept = 0.0288, s.e. = 0.0066). The P values from the meta-analysis strongly 
deviated from the expected (Supplementary Fig. 8) but the trend was consistent 
with polygenicity (LDSC intercept = 1.0048, s.e. = 0.008) rather than uncontrolled 
inflation74. In this new meta-analysis, we identified 61 independent loci associated 
with Parkinson’s disease (49 reported previously17 and 12 novel; Supplementary  
Fig. 9). The 10,000 most associated SNPs from the 23andMe cohort are available  
in Supplementary Table 12.
Gene expression data. We collected publicly available single-cell RNA-seq data from 
different studies. The core dataset of our analysis is a study that sampled more than 
500,000 single cells from the entire mouse nervous system (19 regions) and identified 
39 broad categories (level 4) and 265 refined cell types (level 5)23. The 39 cell types 
expressed a median of 16,417 genes, had a median unique molecular identifier 
(UMI) total count of ~8.6 million and summed the expression of a median of 1,501 
single cells (Supplementary Table 13). The replication datasets were: a mouse study 
that sampled 690,000 single cells from 9 brain regions (frontal cortex, striatum, 
globus pallidus externus/nucleus basalis, thalamus, hippocampus, posterior cortex, 
entopeduncular nucleus/subthalamic nucleus, substantia nigra/ventral tegmental 
area and cerebellum) and identified 565 cell types34 (note that we averaged the UMI 
counts by broad categories of cell type in each brain region, resulting in 88 different 
cell types); our prior mouse study of ~10,000 cells from 5 different brain regions (and 
samples enriched for oligodendrocytes, dopaminergic neurons, serotonergic neurons 
and cortical parvalbuminergic interneurons) that identified 24 broad categories and 
149 refined cell types11; a study that sampled 19,550 nuclei from frozen adult human 
post-mortem hippocampus and prefrontal cortex and identified 16 cell types35; a 
study that generated 36,166 single-nuclei expression measurements (after quality 
control) from the human visual cortex, frontal cortex and cerebellum36. We also 
obtained bulk-tissue RNA-seq gene expression data from 53 tissues from the GTEx 
consortium7 (v8, median across samples).
Gene expression data processing. All datasets were processed uniformly. First we 
computed the mean expression for each gene in each cell type from the single-cell 
expression data (if this statistic was not provided by the authors). We used the 
pre-computed median expression across individuals for the GTEx dataset and 
excluded tissues that were not sampled in at least 100 individuals, non-natural 
tissues (for example, Epstein–Barr virus–transformed lymphocytes) and testis 
tissues (outlier using hierarchical clustering). We then averaged the expression of 
tissues by organ (with the exception of brain tissues) resulting in gene expression 
profiles of a total of 37 tissues. For all datasets, we filtered out any genes with 
non-unique names, genes not expressed in any cell types, non-protein-coding 
genes and, for mouse datasets, genes that had no expert-curated 1:1 orthologs 
between mice and humans (Mouse Genome Informatics, The Jackson Laboratory, 
version 11/22/2016). Gene expression was then scaled to a total of 1 million UMIs 
(or transcripts per million (TPM)) for each cell type/tissue. We then calculated 
a metric of gene expression specificity by dividing the expression of each gene in 
each cell type by the total expression of that gene in all cell types, leading to values 
ranging from 0 to 1 for each gene (0: meaning that the gene is not expressed in that 
cell type; 0.6: that 60% of the total expression of that gene is performed in that cell 
type; 1: that 100% of the expression of that gene is performed in that cell type). 
The 10% most specific genes (Supplementary Tables 14 and 15) in each tissue/cell 
type partially overlapped for related tissues/cell types, did not overlap for unrelated 
tissue/cell types and allowed us to cluster related tissues/cell types as expected 
(Supplementary Figs. 10 and 11).
MAGMA primary and conditional analyses. MAGMA (v1.06b)18 is a software for 
gene-set enrichment analysis using GWAS summary statistics. Briefly, MAGMA 
computes a gene-level association statistic by averaging P values of SNPs located 
around a gene (taking into account LD structure). The gene-level association 
statistic is then transformed to a z score. MAGMA can then be used to test whether 
a gene set is a predictor of the gene-level association statistic of the trait (z score) 
in a linear regression framework. MAGMA accounts for a number of important 
covariates such as gene size, gene density, mean sample size for tested SNPs per 
gene, the inverse of the minor allele counts per gene and the log of these metrics.
For each GWAS summary statistic, we excluded any SNPs with INFO 
score <0.6, with minor allele frequency <1% or with estimated odds ratio 
>25 or smaller than 1/25, the major histocompatibility complex region (chr6: 
25–34 Mb) for all GWAS and the APOE region (chr19: 45020859–45844508) for
the Alzheimer’s GWAS. We set a window of 35 kilobases (kb) upstream to 10 kb 
downstream of the gene coordinates to compute gene-level association statistics 
and used the European reference panel from phase 3 of the 1000 Genomes 
Project75 as the reference population. For each trait, we then used MAGMA to
test whether the 10% most specific gene in each tissue/cell type was associated 
with gene-level genetic association with the trait. Only genes with at least 
1 TPM or 1 UMI per million in the tested cell type were used for this analysis. 
The significance level of the different cell types was highly correlated with the 
effect size of the cell type (Supplementary Fig. 12), with values ranging between 
0.999 and 1 across the 18 brain-related traits in the Zeisel et al. dataset23. The 
significance threshold was set to a 5% false discovery rate across all tissues/cell 
types and traits within each dataset.
MAGMA can also perform conditional analyses given its linear regression 
framework. We used MAGMA to test whether cell types were associated with a 
specific trait conditioning on the gene-level genetic association of another trait  
(z score from MAGMA.out file) or to look for associations of cell types 
conditioning on the 10% most specific genes from other cell types by adding these 
variables as covariates in the model.
To test whether MAGMA was well calibrated, we randomly permuted the  
gene labels of the schizophrenia gene-level association statistic file a thousand 
times. We then looked for association between the 10% most specific genes in  
each cell type and the randomized gene-level schizophrenia association statistics. 
We observed that MAGMA was slightly conservative with less than 5% of the 
random samplings having P < 0.05 (Supplementary Fig. 13).
We also evaluated the effect of varying the window size (for the SNP to gene 
assignment step of MAGMA) on the schizophrenia cell-type association strength 
(−log10[P]). We observed strong Pearson correlations in the cell-type association 
strength (−log10[P]) across the different window sizes tested (Supplementary  
Fig. 14). Our selected window size (35 kb upstream to 10 kb downstream) had 
Pearson correlations ranging from 0.94 to 0.98 with the other window sizes, 
indicating that our results are robust to this parameter.
In a recent paper, Watanabe et al.76 introduced a different methodology to test 
for association between cell type and complex traits based on MAGMA. Their 
proposed methodology tests for a positive relationship between gene expression 
levels and gene-level genetic associations with a complex trait (using all genes). 
Their method uses the average expression of each gene in all cell types in the 
dataset as a covariate. We examined the method of Watanabe et al. in detail, and 
decided against its use for multiple reasons.
First, Watanabe et al. hypothesize that genes with higher levels of expression 
should be more associated with a trait. In extended discussions among our team 
(which includes multiple neuroscientists), we have strong reservations about the 
appropriateness and biological meaningfulness of this hypothesis; it is a strong 
requirement and is at odds with decades of neuroscience research where molecules 
expressed at low levels can have a profound biological impact. For instance, many 
cell-type-specific genes that are disease relevant are expressed at moderate levels 
(for example, Drd2 is in the 10% most specific genes in telencephalon projecting 
inhibitory neurons but in the bottom 30% of expression levels). Our method does 
not make this hypothesis.
Second, the method of Watanabe et al. corrects for the average expression of 
all cell types in a dataset. This practice is, in our view, problematic as it necessarily 
forces dependence on the composition of a scRNA-seq dataset. For instance, if 
a dataset consists mostly of neurons, this amounts to correcting for neuronal 
expression and necessarily erodes power to detect trait enrichment in neurons. 
Alternatively, if a dataset is composed mostly of non-neuronal cells, this will 
impact the detection of enrichment in non-neuronal cells.
Third, preliminary results indicate that the method of Watanabe et al. is 
sensitive to scaling. As different cell types express different numbers of genes, 
scaling to the same total read counts affects the average gene expression across 
cell types (which they use as a covariate), leading to different results with different 
choices of scaling factors (for example, scaling to 10,000 versus 1 million reads). 
Our method is not liable to this issue.
LD score regression analysis. We used partitioned LD score regression19 to test 
whether the 10% most specific genes of each cell type (based on our specificity 
metric described above) were enriched in heritability for the diverse traits. Only 
genes with at least 1 TPM or 1 UMI per million in the tested cell type were used 
for this analysis. To capture most regulatory elements that could contribute to 
the effect of the region on the trait, we extended the gene coordinates by 100 kb 
taking age and sex as covariates. The Lesnick dataset37 was obtained from GEO 
(accession code GSE7621). Data were processed as for the Moran dataset: 
however, age was not available to use as a covariate. The Disjkstra dataset41 was 
obtained from GEO (accession code GSE49036) and processed as above: the sex 
and RNA integrity number values were used as covariates. As the transcriptome 
datasets measured gene expression in the substantia nigra, we kept only cell 
types that are present in the substantia nigra or ventral midbrain for our EWCE10 
analysis. We computed a new specificity matrix based on the substantia nigra or 
ventral midbrain cells from the Zeisel dataset (level 5) using EWCE10. The EWCE 
analysis was performed on the 500 most upregulated or downregulated genes 
using 10,000 bootstrapping replicates.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All single-cell expression data are publicly available. Most summary statistics 
used in this study are publicly available. The migraine GWAS60 can be obtained 
by contacting the authors of that study. The full Parkinson’s disease summary 
statistics from 23andMe can be obtained under an agreement that protects the 
privacy of 23andMe research participants (https://research.23andme.com/
collaborate/#publication). The 10,000 most associated SNPs from the 23andMe 
cohort are available in Supplementary Table 12.
Code availability
The code used to generate these results is available at https://github.com/jbryois/
scRNA_disease. An R package for performing cell-type enrichments using MAGMA 
is also available from https://github.com/NathanSkene/MAGMA_Celltyping.
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upstream and by 100 kb downstream of each gene as previously12. SNPs located  
in 100-kb regions surrounding the 10% most specific genes in each cell type  
were added to the baseline model (consisting of 53 different annotations) 
independently for each cell type (1 file for each cell type). We then selected the 
coefficient z-score P value as a measure of the association of the cell type with the 
traits. The significance threshold was set to a 5% false discovery rate across all 
tissues/cell types and traits within each dataset. All plots show the mean −log10[P] 
of partitioned LDscore regression and MAGMA. All results for MAGMA or LDSC 
are available in supplementary data files (Supplementary Tables 1, 2 and 5–9).
We evaluated the effect of varying the window size and varying the percentage 
of most specific genes on the schizophrenia cell-type association strength  
(−log10[P]). We observed strong Pearson correlations in the cell-type association 
strength (−log10[P]) across the different percentages and window sizes tested 
(Supplementary Fig. 15). Our selected window size (100 kb upstream to 100 kb 
downstream, 10% most specific genes) had Pearson correlations ranging from  
0.96 to 1 with the other window sizes and percentages, indicating that our results 
are robust to these parameters.
MAGMA versus LDSC ranking. To test whether the cell-type rankings obtained 
using MAGMA and LDSC in the Zeisel et al. dataset23 were similar, we computed 
the Spearman rank correlation of the cell-type association strength (−log10[P]) 
between the two methods for each complex trait. The Spearman rank correlation 
was strongly correlated with λGC (a measure of the deviation of the GWAS test 
statistics from the expected; Spearman correlation = 0.89; Supplementary Fig. 16)  
and with the average number of cell types below our stringent significance 
threshold (Spearman correlation = 0.92), indicating that the overall ranking of the 
cell types is very similar between the two methods, provided that the GWAS is 
well powered (Supplementary Fig. 17). In addition, we found that λGC was strongly 
correlated with the strength of association of the top tissue (−log10[P]; Spearman 
correlation = 0.88; Supplementary Fig. 18), as well as with the effect size (beta) 
of the top tissue (Spearman correlation = 0.9), indicating that the associations 
between cell type and trait are stronger for well-powered GWASs. The significance 
level (−log10[P]) was also strongly correlated with the effect size (Spearman 
correlation = 0.996; Supplementary Fig. 18) for the top cell type of each trait.
Dendritic depletion analysis. This analysis was performed as previously 
described11. In brief, all datasets were reduced to a set of six common cell types: 
pyramidal neurons, interneurons, astrocytes, microglia and oligodendrocyte 
precursors. Specificity was recalculated using only these six cell types. Comparisons 
were then made between pairs of datasets (denoted in the graph with the format 
‘X versus Y’). The difference in specificity for a set of dendrite-enriched genes is 
calculated between the datasets. Differences in specificity are also calculated for 
random sets of genes selected from the background gene set. The probability and 
z score for the difference in specificity for the dendritic genes is thus estimated. 
Dendritically enriched transcripts were obtained from Supplementary Table 10 
of Cajigas et al.77. For the KI dataset11, we used S1 pyramidal neurons. For the 
Zeisel 2018 dataset23, we used all ACTE* cells as astrocytes, TEGLU* as pyramidal 
neurons, TEINH* as interneurons, OPC as oligodendrocyte precursors and MGL* 
as microglia. For the Saunders dataset34, we used all Neuron.Slc17a7 cell types from 
FC, HC or PC as pyramidal neurons; all Neuron.Gad1Gad2 cell types from FC, 
HC or PC as interneurons; Polydendrocye as OPCs; Astrocyte as astrocytes, and 
Microglia as microglia. The Lake datasets both came from a single publication36 
that had data from the frontal cortex, visual cortex and cerebellum. The cerebellum 
data were not used here. Data from frontal and visual cortices were analyzed 
separately. All other datasets were used as described in our previous publication11. 
The code and data for this analysis are available as an R package (see ‘Code 
availability’ below).
GO term enrichment. We tested whether genes that were highly specific to a 
trait-associated cell type (top 20% in a given cell type) and highly associated with 
the genetics of the traits (top 10% MAGMA gene-level genetic association) were 
enriched in biological functions using the topGO R package78. As background, we 
used genes that were highly specific to the cell type (top 20%) or highly associated 
with the trait (top 10% MAGMA gene-level genetic association).
Parkinson’s disease rare variant enrichments. We searched the literature for genes 
associated with parkinsonism on the basis of rare and familial mutations. We found 
66 genes (listed in Supplementary Table 10). We used linear regression to test 
whether the z-scaled specificity metrics (per cell type) of the 66 genes were greater 
than 0 in the different cell types.
Parkinson’s disease post-mortem transcriptomes. The Moran dataset38 was 
obtained from GEO (accession code GSE8397). Processing of the U133a and 
U133b Cel files was performed separately. The data were read in using the 
ReadAffy function from the R affy package79; then robust multi-array averaging 
was applied. The U133a and U133b array expression data were merged after 
applying robust multi-array averaging. Probe annotation and mapping to HUGO 
Gene Nomenclature Committee symbols were performed using the biomaRt 
R package80. Differential expression analysis was performed using limma81 
(Vetenskapsrådet, award: 538-2013-8864) and the Klarman Family Foundation. This 
work is supported by the UK Dementia Research Institute, which receives its funding 
from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and 
Alzheimer’s Research UK. We thank the research participants from 23andMe and other 
cohorts for their contribution to this study.
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Extended Data Fig. 1 | Enrichment of immune genes in GTEx tissues. Enrichment pvalues of genes belonging to the GO term ‘Immune System Process’ in 
the 10% most specific genes in each tissue. The one-sided pvalues were computed using linear regression, testing whether the average specificity metric 
of the gene set was higher than 0 (z-scaled specificity metrics per tissue). The GO term was selected because it is the most associated with inflammatory 
bowel disease using MAGMA.
Extended Data Fig. 2 | Associations of brain related traits with cell types from the entire mouse nervous system. Associations of the top 15 most 
associated cell types are shown. The mean strength of association (-log10P) of MAGMA and LDSC is shown and the bar color indicates whether the cell 
type is significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate).
Extended Data Fig. 3 | Correlation in cell type associations across traits. The Spearman rank correlations between the cell types associations across 
traits (-log10P) are shown. SCZ (schizophrenia), EDU (educational attainment), INT (intelligence), BMI (body mass index), BIP (bipolar disorder), NEU 
(neuroticism), PAR (Parkinson’s disease), MDD (Major depressive disorder), MEN (age at menarche), ICV (intracranial volume), ASD (autism spectrum 
disorder), STR (stroke), AN (anorexia nervosa), MIG (migraine), ALS (amyotrophic lateral sclerosis), ADHD (attention deficit hyperactivity disorder), ALZ 
(Alzheimer’s disease), HIP (hippocampal volume).
Extended Data Fig. 4 | Associations of brain related traits with neurons from the central nervous system. Associations of the 15 most associated 
neurons from the central nervous system (CNS) are shown. The specificity metrics were computed only using neurons from the CNS. The mean strength 
of association (-log10P) of MAGMA and LDSC is shown and the bar color indicates whether the cell type is significantly associated with both methods, one 
method or none (significance threshold: 5% false discovery rate).
Extended Data Fig. 5 | Associations of cell types with schizophrenia/cognitive traits conditioning on gene-level genetic association of cognitive traits/
schizophrenia. MAGMA association strength for each cell type before and after conditioning on gene-level genetic association for another trait. The black 
bar represents the significance threshold (5% false discovery rate). SCZ (schizophrenia), INT (intelligence), EDU (educational attainment).
Extended Data Fig. 6 | Replication of cell type—trait associations in 88 cell types from 9 different brain regions. The mean strength of association 
(-log10P) of MAGMA and LDSC is shown for the 15 top cell types for each trait. The bar color indicates whether the cell type is significantly associated with 
both methods, one method or none (significance threshold: 5% false discovery rate).
Extended Data Fig. 7 | Correlation in cell type associations across traits in a replication data set (88 cell types, 9 brain regions). Spearman rank 
correlations for cell types associations (-log10P) across traits are shown. SCZ (schizophrenia), EDU (educational attainment), INT (intelligence), BMI 
(body mass index), BIP (bipolar disorder), NEU (neuroticism), PAR (Parkinson’s disease), MDD (Major depressive disorder), MEN (age at menarche), ICV 
(intracranial volume), ASD (autism spectrum disorder), STR (stroke), AN (anorexia nervosa), MIG (migraine), ALS (amyotrophic lateral sclerosis), ADHD 
(attention deficit hyperactivity disorder), ALZ (Alzheimer’s disease), HIP (hippocampal volume).
Extended Data Fig. 8 | Associations of brain related traits with neurons from 9 different brain regions. Trait—neuron association are shown for neurons 
of the 9 different brain regions. The specificity metrics were computed only using neurons. The mean strength of association (-log10P) of MAGMA and 
LDSC is shown and the bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 
5% false discovery rate).
Extended Data Fig. 9 | Top associated cell types with brain related traits among 24 cell types from 5 different brain regions. The mean strength of 
association (-log10P) of MAGMA and LDSC is shown for the 15 top cell types for each trait. The bar color indicates whether the cell type is significantly 
associated with both methods, one method or none (significance threshold: 5% false discovery rate).
Extended Data Fig. 10 | Top associated neurons with brain related traits among 16 neurons from 5 different brain regions. The specificity metrics were 
computed only using neurons. The mean strength of association (-log10P) of MAGMA and LDSC is shown for the top 15 cell types for each trait. The bar 
color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold= 5% false discovery rate).
